Vivos Therapeutics (VVOS) Panoramica del titolo
Vivos Therapeutics, Inc. opera come società di tecnologia medica e servizi sanitari che sviluppa e commercializza modalità di trattamento per pazienti con anomalie dento-facciali, apnea ostruttiva del sonno (OSA) e russamento negli adulti. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 0/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
+ 2 più rischi
VVOS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Vivos Therapeutics, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$0.28 |
| Massimo di 52 settimane | US$5.12 |
| Minimo di 52 settimane | US$0.26 |
| Beta | 6.09 |
| Variazione di 1 mese | -32.71% |
| Variazione a 3 mesi | -54.25% |
| Variazione di 1 anno | -93.93% |
| Variazione a 3 anni | -95.77% |
| Variazione a 5 anni | -99.78% |
| Variazione dall'IPO | -99.88% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Jul 30
VVOS: Balance Sheet Repair And Rights Offering Will Drive Future Rebound
Analysts have reduced their price target on Vivos Therapeutics stock from $1.75 to $0.75, citing a need for significant balance sheet reinforcement and an increased risk of equity dilution. What’s in the News for Vivos Therapeutics Vivos Therapeutics received a Nasdaq notice on June 5, 2026, that its common stock no longer meets the minimum bid price requirement of US$1.00 per share, with a 180 day window through December 2, 2026, to regain compliance.
Aggiornamento narrativa • Jul 16
VVOS: Insomnia Data And New Partnerships Will Drive Future Upside
Analysts have reduced the fair value estimate for Vivos Therapeutics from $2.45 to about $2.12, citing lower price targets and concern that the balance sheet may require significant reinforcement, which could mean higher expected equity dilution. Analyst Commentary Recent Street research on Vivos Therapeutics highlights a mix of cautious and neutral stances, with multiple price target cuts following the latest earnings update and concerns about the company’s balance sheet and equity dilution risk.Aggiornamento narrativa • Jul 02
VVOS: Insomnia Study And New Partnerships Will Drive Future Upside
Analysts have reduced their price target on Vivos Therapeutics to $2.45 from $5.83, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent research on Vivos Therapeutics highlights a mix of cautious and constructive views, with the lower price targets reflecting updated assumptions on discount rates, revenue growth, margins, and future P/E levels rather than a single headline issue.Recent updates
Aggiornamento narrativa • Jul 30
VVOS: Balance Sheet Repair And Rights Offering Will Drive Future Rebound
Analysts have reduced their price target on Vivos Therapeutics stock from $1.75 to $0.75, citing a need for significant balance sheet reinforcement and an increased risk of equity dilution. What’s in the News for Vivos Therapeutics Vivos Therapeutics received a Nasdaq notice on June 5, 2026, that its common stock no longer meets the minimum bid price requirement of US$1.00 per share, with a 180 day window through December 2, 2026, to regain compliance.Aggiornamento narrativa • Jul 16
VVOS: Insomnia Data And New Partnerships Will Drive Future Upside
Analysts have reduced the fair value estimate for Vivos Therapeutics from $2.45 to about $2.12, citing lower price targets and concern that the balance sheet may require significant reinforcement, which could mean higher expected equity dilution. Analyst Commentary Recent Street research on Vivos Therapeutics highlights a mix of cautious and neutral stances, with multiple price target cuts following the latest earnings update and concerns about the company’s balance sheet and equity dilution risk.Aggiornamento narrativa • Jul 02
VVOS: Insomnia Study And New Partnerships Will Drive Future Upside
Analysts have reduced their price target on Vivos Therapeutics to $2.45 from $5.83, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent research on Vivos Therapeutics highlights a mix of cautious and constructive views, with the lower price targets reflecting updated assumptions on discount rates, revenue growth, margins, and future P/E levels rather than a single headline issue.Aggiornamento narrativa • Jun 18
VVOS: Compliance Progress And Capital Raises Will Support Future Stock Rebound
Analysts have adjusted their price target on Vivos Therapeutics downward by several dollars to reflect revised growth expectations, updated discount rate assumptions, and a higher projected future P/E multiple, as illustrated by recent target cuts to $4.50 and $0.75. Analyst Commentary Recent research on Vivos Therapeutics highlights a more cautious tone, with bearish analysts revisiting their assumptions on growth, valuation, and execution risk.Aggiornamento narrativa • Jun 03
VVOS: Nasdaq Compliance Plan And Fresh Capital Will Support Future Rebound
Narrative Update: Vivos Therapeutics Analysts have cut their price targets on Vivos Therapeutics by amounts including $4.50 and $0.75, citing updated assumptions for revenue growth, profit margin, discount rate, and future P/E that together support a refreshed fair value estimate of $1.75 per share. Analyst Commentary Recent research updates on Vivos Therapeutics point to more cautious sentiment, with analysts trimming price targets and resetting expectations around revenue growth, margins, discount rates, and future P/E assumptions.Aggiornamento narrativa • May 14
VVOS: Nasdaq Compliance Plan And New Funding Will Support Future Upside Potential
Narrative Update on Vivos Therapeutics Analysts have trimmed their price targets on Vivos Therapeutics by a combined $5.25, citing updated assumptions for fair value, a higher discount rate, more moderate revenue growth, slightly higher profit margins, and a higher future P/E multiple. Analyst Commentary Recent Street research on Vivos Therapeutics points to a more cautious tone among bearish analysts, reflected in reduced price targets that incorporate updated assumptions around discount rates, revenue trajectories, margins, and valuation multiples.
Aggiornamento narrativa • Apr 28
VVOS: Future Revenue Execution Could Support Rebased Bullish Outlook
Analysts have revised their fair value estimate for Vivos Therapeutics from $6.50 to $3.00, citing updated views on required discount rates, revenue growth assumptions, profit margins, and a lower future P/E multiple. Analyst Commentary Recent Street research on Vivos Therapeutics has focused on recalibrating price targets to reflect updated assumptions around discount rates, revenue trajectories, profitability, and future P/E multiples.Aggiornamento narrativa • Apr 12
VVOS: Expanded Sleep Apnea Study And New Funding Will Support Future Upside Potential
Analysts have nudged their price target on Vivos Therapeutics higher to $2.50 from $2.40, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E. These revisions modestly refine their view of the stock's risk and earnings power.Aggiornamento narrativa • Mar 28
VVOS: Expanded Sleep Apnea Treatment Indications Will Support Future Upside Potential
Analysts have adjusted their price target on Vivos Therapeutics to $2.50 from $2.50. This reflects updated views on discount rates, revenue growth, profit margins and future P/E assumptions, while keeping the overall valuation level unchanged.Aggiornamento narrativa • Mar 14
VVOS: Sleep Center And Digital Sleep Tools Expansion Will Support Upside Potential
Analysts held their $2.50 price target for Vivos Therapeutics, citing only slight shifts in their modeled discount rate, revenue growth, profit margin, and future P/E assumptions that together keep their overall valuation view broadly unchanged. What's in the News Filed a follow on equity offering of up to US$6 million in common stock, covering 75,000,000 shares at an indicated price of US$0.08 per share (Follow on Equity Offering).Aggiornamento narrativa • Feb 27
VVOS: Sleep Center Expansion And Partnerships Will Support Future Upside Potential
Analysts have adjusted their price target for Vivos Therapeutics slightly, reflecting small shifts in discount rate, expected revenue growth, profit margin outlook, and assumed future P/E. They now view the shares as fairly valued around $2.50.Aggiornamento narrativa • Feb 09
VVOS: New Sleep Center Expansion Will Support Future Upside Potential
Analysts have adjusted their price target on Vivos Therapeutics to an updated US$2.50, reflecting refreshed assumptions around discount rates, revenue growth, profit margins and forward P/E that together refine their view of the stock's risk and earnings profile. What's in the News Vivos Therapeutics entered a collaboration with SoundHealth to distribute SoundHealth's Sonu Band and Spatial Sleep band through Vivos' network of over 2,000 trained dentists, sleep healthcare providers, and affiliated sleep testing centers, with Vivos acting as a reseller across its network (Client Announcements).Aggiornamento narrativa • Jan 26
VVOS: New Sleep Center And Financing Will Support Future Upside Potential
Analysts have trimmed their price target on Vivos Therapeutics to reflect a slightly higher discount rate and a modest adjustment in projected profit margins. Revenue growth assumptions and future P/E expectations remain broadly consistent, leading to a revised fair value estimate of around $2.50 per share.Aggiornamento narrativa • Jan 10
VVOS: Sleep Center Affiliations Will Drive Future Upside Potential
Analysts have reduced their fair value estimate for Vivos Therapeutics from $4.00 to $2.50, citing updated assumptions that combine a higher discount rate with significantly faster modeled revenue growth, a slightly adjusted profit margin profile, and a lower future P/E multiple in their valuation analysis. What's in the News Opened a new sleep testing and treatment center near Detroit in Auburn Hills, Michigan, extending its sleep center affiliation model that already operates in Las Vegas, Nevada (Key Developments).Aggiornamento narrativa • Nov 21
VVOS: Significant Clinical Findings Will Drive Upside in 2024
Analysts have raised their price target for Vivos Therapeutics from $5.10 to $5.83 per share. They cited improved revenue growth projections and modest adjustments to future profitability assumptions.Aggiornamento narrativa • Aug 22
Acquisitions And Sleep Center Integrations Will Expand Future Markets
The sharp upward revision in the analyst price target for Vivos Therapeutics reflects markedly improved revenue growth forecasts and a lower future P/E multiple, raising fair value from $4.22 to $5.10. What's in the News Vivos Therapeutics will be unable to file its next 10-Q by the SEC deadline.Articolo di analisi • Jul 02
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Stock Rockets 60% As Investors Are Less Pessimistic Than Expected
The Vivos Therapeutics, Inc. ( NASDAQ:VVOS ) share price has done very well over the last month, posting an excellent...
Nuova narrativa • Apr 15
FDA Clearance And Middle East Expansion Will Secure Future Success
Strategic alliances and clinic acquisitions aim to increase patient conversions, boosting revenue and margins through higher treatment uptake.Articolo di analisi • Apr 05
Positive Sentiment Still Eludes Vivos Therapeutics, Inc. (NASDAQ:VVOS) Following 26% Share Price Slump
Unfortunately for some shareholders, the Vivos Therapeutics, Inc. ( NASDAQ:VVOS ) share price has dived 26% in the last...Articolo di analisi • Feb 16
Investors Give Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares A 30% Hiding
Vivos Therapeutics, Inc. ( NASDAQ:VVOS ) shares have retraced a considerable 30% in the last month, reversing a fair...Articolo di analisi • Dec 27
After Leaping 35% Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares Are Not Flying Under The Radar
Despite an already strong run, Vivos Therapeutics, Inc. ( NASDAQ:VVOS ) shares have been powering on, with a gain of...Articolo di analisi • Nov 12
Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely
Vivos Therapeutics, Inc. ( NASDAQ:VVOS ) shares have continued their recent momentum with a 27% gain in the last month...Articolo di analisi • Sep 10
Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story
Vivos Therapeutics, Inc. ( NASDAQ:VVOS ) shareholders would be excited to see that the share price has had a great...Articolo di analisi • Apr 25
It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks
Vivos Therapeutics, Inc. ( NASDAQ:VVOS ) shareholders that were waiting for something to happen have been dealt a blow...Articolo di analisi • Feb 02
It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks
Vivos Therapeutics, Inc. ( NASDAQ:VVOS ) shares have retraced a considerable 48% in the last month, reversing a fair...Rendimenti per gli azionisti
| VVOS | US Healthcare | US Mercato | |
|---|---|---|---|
| 7D | -8.6% | -1.5% | -2.1% |
| 1Y | -93.9% | 23.0% | 18.8% |
Ritorno vs Industria: VVOS ha avuto una performance inferiore rispetto al US Healthcare che ha registrato un rendimento 23 % nell'ultimo anno.
Rendimento vs Mercato: VVOS ha avuto una performance inferiore al mercato US che ha registrato un rendimento 18.8 % nell'ultimo anno.
Volatilità dei prezzi
| VVOS volatility | |
|---|---|
| VVOS Average Weekly Movement | 17.6% |
| Healthcare Industry Average Movement | 7.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di VVOS è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 18% ) di VVOS è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2016 | 270 | R. Huntsman | www.vivos.com |
Vivos Therapeutics, Inc. opera come società di tecnologia medica e servizi sanitari che sviluppa e commercializza modalità di trattamento per pazienti con anomalie dento-facciali, apnea ostruttiva del sonno (OSA) e russamento negli adulti. Offre il Metodo Vivos, una modalità di trattamento multidisciplinare non invasiva, non chirurgica e non farmaceutica per il trattamento delle anomalie dento-facciali, dell'OSA e del russamento. L'azienda offre anche il programma VivoScore, uno screening e un test del sonno a domicilio per adulti e bambini.
Vivos Therapeutics, Inc. Riepilogo dei fondamenti
| VVOS statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$3.83m |
| Utili (TTM) | -US$25.46m |
| Ricavi(TTM) | US$20.90m |
0.2x
Rapporto P/S-0.2x
Rapporto P/EVVOS è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| VVOS Conto economico (TTM) | |
|---|---|
| Ricavi | US$20.90m |
| Costo del fatturato | US$7.96m |
| Profitto lordo | US$12.94m |
| Altre spese | US$38.39m |
| Utili | -US$25.46m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -1.83 |
| Margine lordo | 61.90% |
| Margine di profitto netto | -121.79% |
| Rapporto debito/patrimonio netto | -204.2% |
Come si è comportato VVOS nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/20 15:47 |
| Prezzo dell'azione a fine giornata | 2026/08/20 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Vivos Therapeutics, Inc. è coperta da 6 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Scott Henry | Alliance Global Partners |
| Lucas Ward | Ascendiant Capital Markets LLC |
| Alexander Nowak | Craig-Hallum Capital Group LLC |